Market Closed - London S.E. 11:35:26 2024-07-17 EDT 5-day change 1st Jan Change
7 GBX 0.00% Intraday chart for IXICO plc 0.00% -44.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ixico Bags Over GBP1 Million Contract for Parkinsonian Disorder Study MT
AIM WINNERS & LOSERS: Ixico and Light Science Technologies win deal AN
Ixico shares jump as wins new pharma contract worth over GBP1 million AN
IXICO plc Announces New Pharma Client Contract Valued in Excess of £1 Million for A Study of A Parkinsonian Disorder CI
Ixico wins deal; United Oil & Gas settles debt AN
IXICO plc Signs Contract with Global Alzheimer's Platform Foundation to Support Bio-Hermes 2 Trial CI
EARNINGS AND TRADING: Topps Tiles in strategic shift as swings to loss AN
Transcript : IXICO plc, H1 2024 Earnings Call, May 21, 2024
Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Revenue GBP2.5M MT
Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Loss GBX-2.92 MT
IXICO plc Reports Earnings Results for the Half Year Ended March 31, 2024 CI
Ixico inks supply agreement with Life Molecular Imaging for Neuraceq AN
IXICO plc Provides Information on Its Agreement with Life Molecular Imaging for the Supply of Neuraceq Amyloid PET Tracer CI
Ixico inks collaboration with IMEKA Solutions AN
IXICO plc Announces Collaboration Agreement with IMEKA Solutions Inc. to Provide Access to Imeka's Suite of Services for White Matter Imaging deployed in Alzheimer's Disease and Multiple Sclerosis Clinical Trials, Amongst Other CNS Indications CI
Ixico shares fall 20% as revenue to decline, hit by delays to projects AN
AIM WINNERS & LOSERS: Woodbois rises as plots Mozambique exit AN
FTSE 100 slips but CAC and DAX hit record highs AN
Ixico CEO Cerroni to retire by end of 2024; starts succession search AN
Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024 CI
Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024 CI
Transcript : IXICO plc, 2023 Earnings Call, Dec 05, 2023
EARNINGS AND TRADING: Ixico revenue falls, Solid State boosts profit AN
IXICO plc Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees CI
Chart IXICO plc
More charts
IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. IXI Stock
  4. News IXICO plc
  5. Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Loss GBX-2.92